DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases.
DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduction in moderate to severe acute exacerbations of COPD, along with improvements in lung function
DUPIXENT significantly improved quality of life, and reductions in the severity, with numerical improvements as early as 4 weeks after initiating treatment
Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory disease that damages ...
